PL1699480T3 - Allogeniczny przeciwnowotworowy czynnik terapeutyczny - Google Patents

Allogeniczny przeciwnowotworowy czynnik terapeutyczny

Info

Publication number
PL1699480T3
PL1699480T3 PL04728317T PL04728317T PL1699480T3 PL 1699480 T3 PL1699480 T3 PL 1699480T3 PL 04728317 T PL04728317 T PL 04728317T PL 04728317 T PL04728317 T PL 04728317T PL 1699480 T3 PL1699480 T3 PL 1699480T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
allogeneic tumor
tumor therapeutic
vaccine
tumor cells
Prior art date
Application number
PL04728317T
Other languages
English (en)
Inventor
Tomislav Dobric
Burghardt Wittig
Manuel Schmidt
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of PL1699480T3 publication Critical patent/PL1699480T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04728317T 2003-12-30 2004-04-20 Allogeniczny przeciwnowotworowy czynnik terapeutyczny PL1699480T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE0304299 2003-12-30
PCT/DE2004/000859 WO2005063280A1 (de) 2003-12-30 2004-04-20 Allogenes tumortherapeutikum
EP04728317A EP1699480B1 (de) 2003-12-30 2004-04-20 Allogenes tumortherapeutikum

Publications (1)

Publication Number Publication Date
PL1699480T3 true PL1699480T3 (pl) 2011-11-30

Family

ID=34716109

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04728317T PL1699480T3 (pl) 2003-12-30 2004-04-20 Allogeniczny przeciwnowotworowy czynnik terapeutyczny

Country Status (12)

Country Link
US (2) US7635468B2 (pl)
EP (1) EP1699480B1 (pl)
JP (1) JP4945247B2 (pl)
CN (3) CN1921882A (pl)
AT (1) ATE512668T1 (pl)
BR (1) BRPI0418157A (pl)
DK (1) DK1699480T3 (pl)
ES (1) ES2366694T3 (pl)
PL (1) PL1699480T3 (pl)
PT (1) PT1699480E (pl)
RU (1) RU2354694C2 (pl)
WO (1) WO2005063280A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1699480T3 (pl) * 2003-12-30 2011-11-30 Mologen Ag Allogeniczny przeciwnowotworowy czynnik terapeutyczny
WO2006015560A1 (de) * 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US20090220931A1 (en) * 2005-09-08 2009-09-03 Mologen Ag Functional in vitro immunoassay
US9499815B1 (en) * 2006-05-11 2016-11-22 Mologen Ag Multimer for immunostimulation
CN101199862B (zh) * 2007-12-19 2011-07-06 北京大学第三医院 B7-1、cd40l质粒混合物
RU2362805C1 (ru) * 2008-02-19 2009-07-27 Институт Биологии Гена Российской Академии Наук Линия клеток меланомы человека kg, секретирующих рекомбинантный гранулоцитарно-макрофагальный колониестимулирующий фактор
RU2395573C1 (ru) * 2008-11-27 2010-07-27 Учреждение Российской Академии Наук Институт Биологии Гена Ран Линия клеток меланомы человека 31g, секретирующих рекомбинантный гранулоцитарно-макрофагальный колониестимулирующий фактор
GB2483462A (en) * 2010-09-08 2012-03-14 Mologen Ag Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
CA2940928C (en) * 2014-04-07 2024-01-09 Lokon Pharma Ab Transmembrane cd154 proteins with oligomerization domain and medical uses thereof
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
US10731128B2 (en) 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
WO2019135701A1 (en) 2018-01-05 2019-07-11 Nilsson Rolf Jonas Andreas Endogenous tumor-derived circular rna and proteins thereof for use as vaccine
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
EP3923979A1 (en) * 2019-02-15 2021-12-22 Rjan Holding AB Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗
CN115919798A (zh) * 2022-11-14 2023-04-07 华中科技大学同济医学院附属协和医院 基于肿瘤细胞外颗粒的肿瘤疫苗及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681562A (en) 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
DE4416784A1 (de) 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
DE4431401A1 (de) * 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6805869B2 (en) * 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP1037643B1 (en) * 1997-10-10 2003-12-03 Meyer Pharmaceuticals, LLC Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
DE19746173A1 (de) * 1997-10-18 1999-04-22 Boehringer Ingelheim Int Tumorvakzine
CN1100879C (zh) 1998-02-23 2003-02-05 上海东方肝胆外科医院 多基因转染的细胞株及其构建方法
DE19832840C1 (de) 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP1355661A2 (de) * 2001-01-31 2003-10-29 Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH Tumorvakzine
WO2002100345A2 (en) 2001-06-11 2002-12-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods of using the same
EP1432439B1 (de) 2001-10-02 2005-12-07 Mologen AG Mittel zur verbesserung der immunantwort
WO2003039591A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2003045428A2 (de) * 2001-11-30 2003-06-05 Medigene Aktiengesellschaft Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
AU2003260243A1 (en) 2002-07-19 2004-03-03 Mologen Ag Dna expression construct for multiple gene expression
DE10234739A1 (de) 2002-07-30 2004-02-12 Universitätsklinikum Hamburg-Eppendorf Splicing-Variante des humanen p53-Proteins und deren Verwendung zur Herstellung pharmazeutischer Präparate zur Behandlung von Tumorerkrankungen
PL1699480T3 (pl) * 2003-12-30 2011-11-30 Mologen Ag Allogeniczny przeciwnowotworowy czynnik terapeutyczny
WO2006063301A1 (en) 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines

Also Published As

Publication number Publication date
US7635468B2 (en) 2009-12-22
CN1921882A (zh) 2007-02-28
JP4945247B2 (ja) 2012-06-06
CN103173460A (zh) 2013-06-26
EP1699480B1 (de) 2011-06-15
US20070160587A1 (en) 2007-07-12
RU2354694C2 (ru) 2009-05-10
US9345754B2 (en) 2016-05-24
BRPI0418157A (pt) 2007-04-17
ES2366694T3 (es) 2011-10-24
PT1699480E (pt) 2011-08-30
WO2005063280A1 (de) 2005-07-14
ATE512668T1 (de) 2011-07-15
CN102994515A (zh) 2013-03-27
JP2007516985A (ja) 2007-06-28
RU2006127428A (ru) 2008-02-10
US20100297189A1 (en) 2010-11-25
EP1699480A1 (de) 2006-09-13
DK1699480T3 (da) 2011-10-10

Similar Documents

Publication Publication Date Title
PT1699480E (pt) AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
TW200505458A (en) 1-amino 1h-imidazoquinolines
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
BR0210628A (pt) Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
PL374865A1 (pl) Leczenie zaburzeń związanych z TNF alfa
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MY140767A (en) Compounds, methods and compositions
GB0109297D0 (en) Vaccine
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
IL146125A0 (en) Novel quinones as disease therapies
EP1778186A4 (en) PROCESS FOR PREPARING POLY-ICLC AND USES THEREOF
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
SI1509244T1 (sl) Nov postopek in spojina za izdelavo celične alogenične vakcine
SI1140168T1 (en) Vaccination against cancer
EP1663377A4 (en) THERAPEUTIC MEDICAL DEVICE, DELIVERY AND METHOD OF USE
WO2002060476A3 (de) Tumorvakzine
TW200513264A (en) Remedy and a therapeutic method for periodontal diseases and pulpal diseases
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
EP1151756A4 (en) USE OF POLYACRYLAMIDE GEL FOR PRODUCING A CAPSULE IN THE TISSUE OF A MAMMAL ORGANISM, METHOD FOR CULTURING CELLS AND METHOD FOR TREATING ONCOLOGICAL DISEASES AND DIABETES MELLITUS
WO2004005554A3 (en) Antisense modulation of livin expression
WO2003106645A3 (en) ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION
AU2002329000A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1